FDA Lifts Clinical Hold on Intellia's Magnitude Phase 3 ATTR-CM Trial
Summary
The FDA has lifted the clinical hold on Intellia Therapeutics' Magnitude Phase 3 clinical trial for ATTR-CM. This is a highly significant positive development for the company, as the removal of a clinical hold on a late-stage trial eliminates a major regulatory hurdle and allows the pivotal study to advance. While Intellia recently provided general positive updates on its clinical pipeline in its Q4/FY2025 results and 2025 annual report on February 26, this specific regulatory clearance for a Phase 3 trial is new and material. This de-risks a key pipeline asset and is crucial for the company's path to potential market approval and future revenue generation. Investors will now closely monitor the trial's progress and upcoming data readouts.
At the time of this announcement, NTLA was trading at $15.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $5.90 to $28.25. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.